Watch for initiation of TELLOMAK-3 enrollment (Q1 2027) and any regulatory feedback on accelerated approval path for lacutamab in Sézary syndrome. Milestone payments and royalty stream will provide non-dilutive funding visibility.
Price Chart
Executive Summary
Innate Pharma's strategic partnership with Sobi for lacutamab is now effective after closing conditions were met, including antitrust clearance. Sobi pays $75M upfront with up to $505M in additional milestones and tiered double-digit royalties, funding the TELLOMAK-3 confirmatory Phase 3 study in CTCL/Sézary syndrome. This de-risks the development path and provides non-dilutive capital, a clear positive for Innate.
Key Financial Metrics
Key Facts
- Partnership effective after antitrust waiting periods and other conditions completed.
- Sobi pays Innate $75 million upfront upon effectiveness.
- Innate eligible for up to $40 million in near-term development milestones for Sézary syndrome.
- Additional up to $465 million in option, regulatory, and commercial milestones.
- Innate receives tiered double-digit royalties on net sales.
- TELLOMAK-3 confirmatory Phase 3 study in CTCL to support accelerated approval filing for Sézary syndrome.
- First patient expected Q1 2027.
- Sobi gets exclusive global commercialization rights upon potential accelerated approval.
Financial Impact
$75M upfront + up to $505M milestones + double-digit royalties
Risk Factors
- Clinical trial risk: TELLOMAK-3 may fail to meet endpoints.
- Regulatory risk: accelerated approval not guaranteed; FDA may require additional data.
- Dependence on Sobi for commercialization and development decisions.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302881377 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.57 | awaiting T+20 | — | $1.46 (−7.01%) |
Oct 20, 2026 6d ago | 6-K | $1.58 | awaiting T+20 | — | $1.46 (−7.48%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.46 (−22.34%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.46 (−32.72%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.46 (−33.03%) |
Aug 10, 2026 11w ago | 6-K | $2.22 $2.05 | ▼ −7.66% | ▼ −6.74% | $1.46 (−34.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers